Omeros (OMER) Total Non-Current Liabilities (2021 - 2026)

Omeros (OMER) reported Total Non-Current Liabilities of $202.1 million for Q1 2026, down 12.36% on a YoY basis from $230.7 million in Q1 2025, and up 20.0% sequentially from $168.5 million in Q4 2025.

Omeros (OMER) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Omeros (OMER) has 6 years of Total Non-Current Liabilities data on file, last reported at $202.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities fell 12.36% year-over-year to $202.1 million; the trailing twelve-month figure through Mar 2026 stood at $202.1 million (down 12.36% YoY), and the FY2025 full-year result was $168.5 million, down 38.2% from the prior year.
  • Total Non-Current Liabilities grew to $202.1 million in Q1 2026, from $168.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $590.5 million in Q4 2022 to a low of $168.5 million in Q4 2025.
  • A 5-year average of $356.9 million and a median of $354.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities jumped 52.88% in 2023 and plunged 47.02% in 2025, its largest moves.
  • Tracing OMER's Total Non-Current Liabilities over 5 years: stood at $590.5 million in 2022, then slumped by 36.3% to $376.2 million in 2023, then dropped by 27.54% to $272.6 million in 2024, then slumped by 38.2% to $168.5 million in 2025, then climbed by 20.0% to $202.1 million in 2026.
  • Business Quant data shows OMER's Total Non-Current Liabilities at $202.1 million in Q1 2026, $168.5 million in Q4 2025, and $181.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Omeros 739.31 Mn 739.31 Mn 9.31 Mn 202.15 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 202.15 Mn
Dec 31, 2025 168.46 Mn
Sep 30, 2025 181.21 Mn
Jun 30, 2025 196.07 Mn
Mar 31, 2025 230.66 Mn
Dec 31, 2024 272.58 Mn
Sep 30, 2024 310.24 Mn
Jun 30, 2024 354.23 Mn
Mar 31, 2024 435.40 Mn
Dec 31, 2023 376.18 Mn
Sep 30, 2023 493.07 Mn
Jun 30, 2023 526.93 Mn
Mar 31, 2023 559.68 Mn
Dec 31, 2022 590.53 Mn
Sep 30, 2022 456.55 Mn
Jun 30, 2022 344.68 Mn
Mar 31, 2022 368.34 Mn
Dec 31, 2021 418.15 Mn